This is a news story, published by Investor's Business Daily, that relates primarily to Moderna news.
For more Moderna news, you can click here:
more Moderna newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Moderna stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest premarket trades news, Stocks news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Covid vaccine maker ModernaInvestor's Business Daily
•Health
Health
80% Informative
Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday .
Sales topped Wall Street's projections, but losses were steeper than expected and Moderna stock toppled.
The company says it submitted three applications for new approvals to the Food and Drug Administration .
It plans to have 10 products on the market by the end of 2027 .
VR Score
80
Informative language
80
Neutral language
19
Article tone
formal
Language
English
Language complexity
41
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links
